ㅤNews
Schistosomiasis Vaccine Development Gains Momentum: Key Outcomes from the 2025 Stakeholders Meeting: Global Experts Unite to Advance the Fight Against Schistosomiasis
March 2025 – The VASA Project and leading global health stakeholders convened at the Schistosomiasis Stakeholder Meeting in Bangkok, Thailand, on January 15-16, 2025, to accelerate the development of a first-ever schistosomiasis vaccine. With millions affected annually by this neglected tropical disease (NTD), the urgency to develop sustainable, long-term solutions has never been greater. The…
VASA Project Achieves Major Milestone: Completion of Phase 1b Enrollment for Schistosomiasis Vaccine Trial
Advancing the Fight Against Schistosomiasis with Rigorous Clinical Research October 2024 – The VASA Project has reached a critical milestone in the development of its schistosomiasis vaccine, successfully completing enrollment for the Phase 1b clinical trial in Madagascar (MIVR) and Burkina Faso (GRAS). This marks a significant step forward in the mission to combat one…
Momentum is building in the Vaccines Against Schistosomiasis for Africa project (VASA)
On August 18 2023, the kickoff investigator meeting for a crucial Phase 1b clinical trial for the Schistoshield® schistosomiasis vaccine took place in the Madagascar Institute for Vaccine Research (MIVR), with partners from the Groupe de Recherche Action Santé (GRAS) in Burkina Faso, the International Vaccine Institute, the University of Cambridge, and Pharmalys. Over half the population of Madagascar (52.1%) is affected by Schistosomiasis, with 107…
Release of new WHO guidelines on control and elimination of human schistosomiasis
WHO provides a new guideline on control and elimination of human schistosomiasis. The goal of this guideline is to provide evidence-based recommendations to countries in their efforts to accomplish schistosomiasis morbidity control and elimination as a public health problem, and to move towards interruption of transmission. Please find more details and the WHO guideline at: https://www.who.int/publications/i/item/9789240041608
Continue Reading Release of new WHO guidelines on control and elimination of human schistosomiasis
News of SchistoShield Phase 1a study initiation
Participant in Kaiser Permanente Washington Health Research Institute (KPWHRI) trial, based in Seattle, received the first injection of the SchistoShield vaccine on May 23, 2022. Participants include healthy people ages 18 through 55 years old, and assigned to different study groups based on when they enroll in the study. The trial assess the safety of the…
Continue Reading News of SchistoShield Phase 1a study initiation
VASA International Stakeholder Meeting in Ouagadougou
The Vaccines Against Schistosomiasis for Africa (VASA) consortium and the International Institute of Science and Technology (IIS Tech) co-hosted the first International Symposium on Tropical Diseases on November 24-26, 2022 in Ouagadougou Burkina Faso. The theme of this meeting was “Technological innovations and the fight against tropical diseases”, and included special highlighted sessions on the…
Continue Reading VASA International Stakeholder Meeting in Ouagadougou
ㅤMedia and Publication
This Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement (No.815643)